Palisade Bio, Inc. · NASDAQ:PALI
Palisade Bio — Investor Presentation (February 2023)
24 slides from Palisade Bio's investor presentation, February 2023
Slide 1: Protecting Intestinal Barrier Health
NASDAQ: PALI | palisadebio.com Protecting Intestinal Barrier Health February 2023 Corporate Presentation
Slide 2: Forward Looking Statements
Forward Looking Statements Statements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding our research and clinical development plans, expected near and long-term milestones,
Slide 3: Palisade Bio Highlights
Palisade Bio Highlights Lead Asset LB1148 Topline Data from Phase 2 prevention of post-surgical We develop therapeutics to abdominal adhesions study expected H1 2023 improve patients’ lives by Commencement of dose optimization study expected H1 2023 protecting intestinal integrity Partner Newsoara c
Slide 4: LB1148 Programs
Clinical Development Pipeline Provides Opportunities Across Multiple High-Value Indications Indication Pre-Clinical Phase 1 Phase 2 Phase 3 NDA Target Milestones Prevention of • Topline data from Phase 2 LB1148 Programs study expected H1 2023 Post-surgical FDA Fast Track GI Surgery • Planning commen
Slide 5: LB1148: Protecting Intestinal Barrier Health
LB1148: Protecting Intestinal Barrier Health Mechanism of Action 5
Slide 6: LB1148 Lead Asset
LB1148 Lead Asset Leverage Scientific Knowledge and Proprietary Technology to Address a Potential Blockbuster Opportunities Novel, Patent Protected Oral Formulation Well-Tolerated with Positive Clear Precedent for Clinical of FDA-Approved Tranexamic Acid Activity in Multiple Clinical Studies Develop
Slide 7: LB1148 Mechanism of Action
— BIO LB1148 Mechanism of Action
Slide 8: LB1148 Protects Intestinal Barrier Health
LB1148 Protects Intestinal Barrier Health Broad-Spectrum Serine Protease Inhibitor Prevents Digestive Enzyme (Trypsin) Driven Tissue Injury Intestinal Barrier Breakdown Hypoperfusion Injury Model Control1 LB1148 • Permeable epithelial barrier • Continuous epithelial barrier • Extensive loss of villi
Slide 9: LB1148: Preventing Post-Surgical Adhesions
LB1148: Preventing Post-Surgical Adhesions Advancing Towards Potential FDA Approval 9
Slide 10: Abdominal Adhesions are a Significant Medical Burden
Abdominal Adhesions are a Significant Medical Burden of abdominal procedures result in 93% post-surgical adhesions #1 cause of small bowel obstruction (up to 75%) Alarming and costs $1.77B in US annually Adhesion #2 cause of female infertility (after menopause) Stats: 80% of emergency surgery deaths
Slide 11: LB1148 Reduced Adhesion Formation by 63% in an Animal Model of GI Surgery
LB1148 Reduced Adhesion Formation by 63% in an Animal Model of GI Surgery Reduced Various Types of Adhesions when Taken Prior to Surgery: Bowel to Bowel | Bowel to Abdominal Wall | Bowel to Viscera Animals Receiving LB1148 Dramatic Reduction in Mean Number Had Fewer Adhesions of Post-Surgical Adhesi
Slide 12: Quantifying Abdominal Adhesions
Quantifying Abdominal Adhesions: Performed Visually During 1st and 2nd Surgeries 1st Surgery 2nd Surgery Bowel Resection and Colostomy Bag Bowel Reconstruction and Adhesion Analysis Intra-Abdominal Adhesions are Graded in Nine Abdominal Regions for Extent and Severity Adhesion Extent Score 0 = no ad
Slide 13: LB1148 Reduced Adhesion Formation in GI Surgery Patients
LB1148 Reduced Adhesion Formation in GI Surgery Patients 40% of LB1148 Treated Subjects Had Zero Clinically Significant Reduction in Adhesions During Follow-up Surgery Extent and Severity of Adhesions 100% 16 Extent and Severity of Adhesions 90% 14 Incidence of Adhesions 80% 70% 55% 1 12 Relative Ri
Slide 14: Phase 2 GI Surgery Study for Prevention of Post-Surgical Abdominal Adhesions
Phase 2 GI Surgery Study for Prevention of Post- Surgical Abdominal Adhesions Topline Data from Phase 2 Study Expected H1 2023 Voluntarily ended enrollment in the trial having enrolled a total of 35 patients Dosing GI Surgery Postoperative Follow-up Adhesion / Discharge Assessment Prior to Surgery L
Slide 15: LB1148: Commercial Opportunity
LB1148: Commercial Opportunity Potential to Reduce Costs for Hospitals and Improve Outcomes 15
Slide 16: Current FDA Approved Options Have Significant Limitations
Current FDA Approved Options Have Significant Limitations Post-Surgical Adhesions Medical device for use during surgery Only reduces adhesions between the abdominal wall and the underlying viscera, not bowel to bowel or bowel to viscera Disrupts surgical process; extends duration of surgery Only App
Slide 17: Commercial Strategy Aligns with Hospital Protocols and Financial Goals
Commercial Strategy Aligns with Hospital Protocols and Financial Goals Does Not Interfere with Surgical Practice Potential to be Covered by Patient’s Pharmacy Insurance Benefit Commercial Goal to Be Incorporated into Hospital Protocol Physician writes Prescription LB1148 Does not prescription filled
Slide 18: Targeting Blockbuster U.S. Market
Targeting Blockbuster U.S. Market 5.6 million 20% market penetration Annual abdominal could translate to >$1B surgeries 1 annual revenue in U.S. 2 1. CDC/NCHS National Hospital Discharge Survey, 2010 18 2. 6.7M patients from (CDC/NCHS National Hospital Discharge Survey, 2010) with 20% market penetra
Slide 19: Corporate Overview
19 = PALISADEBIO, — Corporate AC Overview > DR
Slide 20: Robust IP Portfolio
Robust IP Portfolio Multiple Layers of Protection Through Early-2037 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 2036 2037 Patent Life 504 Family: 3 components of LB1148 (TXA, PEG, Electrolytes)1 Issued US 9,504,736 (Composition) 505 Family: 4 components of LB1148 (TXA, PEG
Slide 21: Management Team
Management Team JD Finley Herbert B. Slade, M.D. Robert McRae Interim Chief Executive Officer Chief Medical Officer Chief Operating Officer and Chief Financial Officer Nicholas McCoy Ryker Willie Vice President Clinical Operations Senior Vice President, Finance and Corporate Controller 21
Slide 22: Financial Snapshot
Financial Snapshot Sufficient Capital to Fund Operations into 2H 2024 Brought in Aggregate Total of $4.9 Million from Early Exercise of Warrants Since December 2022 ~10.6M 568K $14M Market Cap 1 Volume 1 Cash 2 Received additional $7.4m in gross proceeds from sale of common shares and exercise of wa
Slide 23: We Are Working to Establish New Standards of Care
We Are Working to Establish New Standards of Care Topline Data from Phase 2 prevention of post-surgical abdominal adhesions study expected H1 2023 Clinically Meaningful Results Reduction in abdominal adhesions and was well-tolerated with positive benefit to risk ratio LB1148 Commercial Strategy Alig
Slide 24: Thank You!
NASDAQ: PALI | palisadebio.com Protecting Intestinal Barrier Health Thank You! Investor Relations JTC Team 833.475.8247 [email protected]